DelveInsight’s “Celiac Disease Treatment Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Celiac Disease, historical and forecasted epidemiology, as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Discover Key Insights into the Celiac Disease Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Celiac Disease Market Report
- In May 2025, Teva Pharmaceutical announced FDA Fast Track designation for TEV-53408, an anti-IL-15 antibody in Phase 2a trials for treating adults with celiac disease on a gluten-free diet.
- In 2024, a landmark study confirmed that ZED1227 successfully prevented gluten-induced intestinal damage by targeting specific molecular mechanisms, marking a significant step forward in celiac disease therapy.
- In July 2024, the Beyond Celiac Coalition engaged with the FDA to advance a patient-centric approach to therapeutic trials, enhancing patient involvement while ensuring scientific rigor in the development of new treatments.
- According to DelveInsight’s estimates, in 2023, the United States represented nearly 50% of the Celiac Disease Diagnosed Prevalent Cases across the 7MM.
- Celiac Disease affects approximately 1 in 100 people worldwide; however, only about 30% are properly diagnosed, highlighting a vast unmet diagnostic need.
- The disease shows a notable gender disparity — in Germany, approximately 60% of diagnosed cases are female.
- In 2023, classical celiac disease comprised approximately 30% of all celiac disease cases in Japan.
- Despite strict adherence to a gluten-free diet, approximately 5% of patients continue to experience symptoms, representing a defined population with inadequate response to the current standard of care.
- The disease is most commonly diagnosed in individuals aged 19-39, with the elderly population remaining substantially underdiagnosed across the 7MM.
- Leading Celiac Disease companies include Entero Therapeutics, Amgen/Provention Bio (a Sanofi Company), Takeda, Teva Pharmaceutical, and others.
- Promising Celiac Disease therapies include Latiglutenase (IMGX003), Ordesekimab, TAK-101, TAK-227, TEV-53408, ZED1227, and others.
Stay Ahead in the Celiac Disease Therapeutics Market with DelveInsight’s Strategic Report @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Celiac Disease Epidemiology Segmentation in the 7MM
- Total Celiac Disease Prevalent Population
- Total Celiac Disease Diagnosed Prevalent Population
- Celiac Disease Gender-specific Diagnosed Prevalent Population
- Celiac Disease Type-specific Diagnosed Prevalent Population (Classical, Non-Classical, Subclinical, Refractory Type I, Refractory Type II)
- Celiac Disease Age-specific Distribution (pediatric, adult, elderly)
- HLA Haplotype Distribution (DQ2 vs. DQ8) across the 7MM
Download the Report to Understand Which Factors Are Driving Celiac Disease Epidemiology Trends @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Celiac Disease: Disease Background and Overview
Celiac Disease is a chronic autoimmune disorder in which ingestion of gluten — a protein found in wheat, barley, and rye — triggers an immune response that progressively damages the lining of the small intestine. The disease is driven by an interaction between genetic predisposition, particularly HLA-DQ2 and HLA-DQ8 haplotypes present in approximately 97% of patients, and environmental exposure to dietary gluten. Upon gluten ingestion, tissue transglutaminase (tTG) deamidates gliadin peptides, increasing their affinity for HLA molecules and activating intestinal CD4+ T cells. The resulting inflammatory cascade causes villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis in the small intestine, impairing nutrient absorption.
Clinical presentation is highly variable. Classical gastrointestinal symptoms — chronic diarrhea, steatorrhea, abdominal distension, bloating, and weight loss — represent only one end of a wide spectrum. Non-classical extraintestinal manifestations, including iron-deficiency anemia refractory to oral therapy, metabolic bone disease, peripheral neuropathy, gluten ataxia, infertility, hepatic transaminase elevation, and dermatitis herpetiformis, are increasingly recognized as common presentations, particularly in adult-onset disease. A substantial proportion of patients are subclinically or silently affected — seropositive with intestinal damage but without overt symptoms — contributing significantly to the global diagnostic gap.
Diagnosis is confirmed through serological testing for anti-tissue transglutaminase IgA (anti-tTG IgA), anti-endomysial IgA (EMA), and deamidated gliadin peptide (DGP) antibodies, followed by duodenal biopsy demonstrating characteristic mucosal changes (Marsh classification). HLA typing serves as a high-negative-predictive-value tool to exclude celiac disease in equivocal presentations. Total IgA measurement is recommended alongside serological testing given the higher prevalence of selective IgA deficiency in celiac patients, which can produce false-negative results.
Refractory Celiac Disease
Refractory Celiac Disease (RCD) is defined as persistent or recurrent malabsorption with villous atrophy despite strict adherence to a gluten-free diet for at least 12 months, in the absence of other explanations including inadvertent gluten exposure or overt malignancy. RCD is classified into two types with markedly different prognoses:
- RCD Type I is characterized by a normal intraepithelial lymphocyte (IEL) phenotype and carries a comparatively more favorable prognosis, with five-year survival rates exceeding 80% in controlled series. Management typically involves open-capsule budesonide, immunosuppressants such as azathioprine or 6-mercaptopurine, and intensive nutritional support.
- RCD Type II is characterized by aberrant clonal IEL populations expressing surface CD3 but lacking normal CD8 and T-cell receptor markers. It carries a significantly worse prognosis with five-year survival rates of 44-58% and a 30-50% risk of progression to enteropathy-associated T-cell lymphoma (EATL), an aggressive and often fatal malignancy. No approved pharmacological therapy exists for RCD Type II, representing the most critical unmet need within the celiac disease spectrum.
Celiac Disease Pipeline Analysis
Latiglutenase (IMGX003): Entero Therapeutics
Latiglutenase is an orally administered mixture of two gluten-specific recombinant proteases designed to degrade immunotoxic proline-rich gluten sequences into physiologically inert fragments within the gastric and intestinal lumen before they reach the intestinal mucosa. By neutralizing antigenic gluten peptides at the point of exposure, latiglutenase acts as a luminal barrier rather than a systemic immunosuppressant, offering a fundamentally different safety profile from immune-modulating approaches. The therapy is designed as an adjunct to a gluten-free diet, providing additional protection against inadvertent gluten exposure — a near-universal challenge for celiac patients — rather than replacing dietary management. Phase II clinical trials have been successfully completed, demonstrating reductions in mucosal injury and serological inflammation markers. The Phase III development plan has been thoroughly reviewed by the Gastrointestinal Division of the US FDA. Latiglutenase holds FDA Fast Track Designation, supporting accelerated regulatory interactions and rolling review eligibility.
Ordesekimab (formerly AMG 714 / PRV-015): Amgen / Provention Bio, a Sanofi Company
Ordesekimab is a fully human monoclonal antibody targeting Interleukin-15 (IL-15), a key cytokine in celiac disease pathogenesis that activates intraepithelial lymphocytes, sustains mucosal inflammation, and drives the aberrant clonal lymphocyte expansion characteristic of Refractory Celiac Disease Type II. IL-15 is overexpressed in the intestinal epithelium of active celiac patients, and its inhibition addresses both the inflammatory and pre-malignant components of disease biology. Currently in Phase IIb development for non-responsive celiac disease as an adjunct to a gluten-free diet, ordesekimab is being developed through a collaboration between Amgen and Provention Bio, a Sanofi company. If confirmed effective in RCD II, its ability to target the cytokine directly driving malignant transformation could represent a disease-modifying intervention in the most severe celiac disease subpopulation.
TAK-101: Takeda
TAK-101 is an investigational nanoparticle-based tolerogenic immunotherapy engineered to induce antigen-specific immune tolerance to gliadin by delivering gluten antigens in a non-inflammatory context. The mechanism involves exposure of gliadin-loaded nanoparticles to hepatic sinusoidal endothelial cells and tolerogenic antigen-presenting cells, triggering expansion of gliadin-specific regulatory T cells (Tregs) that suppress the immune response to subsequent gluten exposure. Rather than blocking downstream inflammation, TAK-101 aims to recalibrate the underlying immune misdirection toward gluten — the root cause of the disease. If successful, this approach could represent the first disease-modifying therapy for celiac disease, potentially enabling partial or complete immune tolerance to gluten exposure over time. TAK-101 holds FDA Fast Track Designation, reflecting its potential to address a serious unmet medical need with a novel mechanism.
TAK-227: Takeda
TAK-227 is an oral Transglutaminase 2 (TG2) inhibitor targeting the enzyme responsible for deamidating gliadin peptides — the post-translational modification that dramatically increases gliadin immunogenicity by creating high-affinity ligands for HLA-DQ2 and HLA-DQ8. Without TG2-mediated deamidation, gliadin fragments bind with significantly lower affinity to HLA molecules and fail to effectively activate pathogenic T cells, thereby attenuating the full inflammatory cascade. Proof of concept for TG2 inhibition has been established by ZED1227, a related compound that demonstrated successful prevention of gluten-induced intestinal damage in a 2024 landmark clinical study. TAK-227’s oral route of administration positions it favorably for long-term patient adherence as a daily adjunct to dietary management.
TEV-53408: Teva Pharmaceutical
TEV-53408 is an anti-IL-15 monoclonal antibody developed by Teva Pharmaceutical, targeting the same IL-15 pathway as ordesekimab with a distinct molecular profile. In May 2025, TEV-53408 received FDA Fast Track Designation for the treatment of adults with celiac disease maintained on a gluten-free diet, reflecting the FDA’s recognition of significant unmet need in this population. The drug is currently in Phase 2a trials evaluating its safety and efficacy as an adjunct to dietary management. The parallel clinical development of two anti-IL-15 agents in celiac disease reflects strong mechanistic validation of the IL-15 pathway and growing pharmaceutical confidence in cytokine targeting as a durable therapeutic strategy for this condition.
Get In-Depth Knowledge on Celiac Disease Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Celiac Disease Emerging Drugs
| Drug Name | Company | Phase | Indication | RoA | MoA | Special Status |
|---|---|---|---|---|---|---|
| Latiglutenase (IMGX003) | Entero Therapeutics | III-ready | Celiac Disease (adjunct to GFD) | Oral | Gluten-degrading recombinant protease | Fast Track Designation |
| Ordesekimab | Amgen/Provention Bio (Sanofi) | IIb | Non-responsive celiac disease | Subcutaneous | IL-15 inhibitor | — |
| TAK-101 | Takeda | II | Celiac Disease | Intravenous | Tolerogenic gliadin nanoparticle | Fast Track Designation |
| TAK-227 | Takeda | I/II | Celiac Disease | Oral | Transglutaminase 2 (TG2) inhibitor | — |
| TEV-53408 | Teva Pharmaceutical | IIa | Celiac Disease (on GFD) | Subcutaneous | Anti-IL-15 antibody | Fast Track Designation |
| ZED1227 | Dr. Falk Pharma | II | Celiac Disease | Oral | Transglutaminase 2 (TG2) inhibitor | — |
Celiac Disease Unmet Needs
- No pharmacological therapy has received regulatory approval for celiac disease in any major market, representing the most fundamental unmet need driving the entire therapeutic pipeline.
- Approximately 70% of celiac disease patients globally remain undiagnosed, reflecting insufficient diagnostic penetration, symptom heterogeneity, and the absence of universal screening programs.
- Approximately 5% of patients fail to achieve mucosal healing despite strict adherence to a gluten-free diet, defining a distinct population with inadequate response to the current standard of care.
- Refractory Celiac Disease Type II lacks any approved therapy, with existing management options demonstrating limited efficacy and a 30-50% risk of progression to enteropathy-associated T-cell lymphoma (EATL).
- Validated, non-invasive biomarkers for real-time monitoring of mucosal healing and early detection of disease complications are absent, limiting therapeutic decision-making and treatment monitoring.
- Current diagnosis requires invasive duodenal biopsy under active gluten exposure, creating access barriers, diagnostic delays, and patient reluctance that perpetuate the diagnostic gap.
- Effective pharmacological options for celiac-associated neurological complications — including gluten ataxia and peripheral neuropathy — remain unavailable beyond dietary restriction.
- Patient-reported outcome instruments for celiac disease lack universal validation across languages, cultures, and healthcare systems, complicating multi-national clinical trial design.
- The social, psychological, and economic burden of strict lifelong dietary management remains inadequately addressed within current treatment algorithms.
Celiac Disease Market Outlook
The Celiac Disease market is at a defining inflection point. For the first time in the disease’s clinical history, a credible pharmacological pipeline is advancing through late-stage development, with multiple candidates approaching or entering pivotal trials. The United States accounted for approximately 70% of the 7MM Celiac Disease drugs market in 2023, reflecting its larger diagnosed patient population, higher per-capita pharmaceutical spending, and advanced healthcare infrastructure. Among EU4 and the UK, Italy led with an estimated market valuation of approximately USD 200 million. In Japan, the gluten-free diet management market was valued at approximately USD 1,500 million in 2023.
The current market is dominated by dietary management products and nutritional supplementation, with no approved prescription pharmacotherapy. The first regulatory approval of a pharmacological celiac disease treatment will fundamentally reshape the market landscape by establishing prescription prescribing patterns, reimbursement frameworks, and clinical treatment algorithms that incorporate drug therapy alongside dietary management. Refractory celiac disease subpopulations — particularly RCD Type II — are expected to attract premium-priced specialty biologics given disease severity, absence of approved options, and potential for orphan drug designation providing market exclusivity and pricing support.
The IL-15 inhibitor class, with two agents (ordesekimab and TEV-53408) in concurrent clinical development, may establish a new standard of care in treatment-refractory patients if Phase II/III data confirms durable clinical benefit. Tolerogenic immunotherapy, represented by TAK-101, offers the possibility of disease modification rather than symptomatic management — a commercial positioning that could command substantial premium pricing if pivotal trial data supports durable immune tolerance induction. The Celiac Disease market is expected to grow at a significant CAGR over the forecast period 2024-2034, driven by new product launches, rising diagnosis rates, expansion of the refractory disease treatment segment, and growing integration of pharmacotherapy into multidisciplinary treatment algorithms.
Celiac Disease Companies
Entero Therapeutics, Amgen/Provention Bio (a Sanofi Company), Takeda, Teva Pharmaceutical, Dr. Falk Pharma, and others.
Scope of the Celiac Disease Market Report
- Coverage: 7MM
- Study Period: 2020-2034
- Forecast Period: 2024-2034
- Celiac Disease Companies: Entero Therapeutics, Amgen/Provention Bio, Takeda, Teva Pharmaceutical, and others
- Celiac Disease Therapies: Latiglutenase, Ordesekimab, TAK-101, TAK-227, TEV-53408, ZED1227, and others
- Celiac Disease Market Access & Reimbursements, Unmet Needs and Perspectives
- Celiac Disease SWOT Analysis and KOL Views
- Celiac Disease Treatment Algorithm and Current Medical Practices
- Celiac Disease Epidemiology: Prevalence, Diagnosis Rates, Gender- and Type-specific Distribution
- Celiac Disease Conjoint Analysis and Competitive Landscape
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Celiac Disease
- Key Events
- Celiac Disease and Market Forecast Methodology
- Celiac Disease Market Overview at a Glance
- Disease Background and Overview: Celiac Disease
- Treatment and Management
- Epidemiology and Patient Population of Celiac Disease in the 7MM
- Patient Journey
- Key Endpoints in Celiac Disease
- Emerging Therapies
- Celiac Disease: Seven Major Market Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
